Literature DB >> 31153636

Adipose tissue macrophage-derived exosomal miR-29a regulates obesity-associated insulin resistance.

Ting Liu1, Yu-Chen Sun1, Peng Cheng2, Hui-Ge Shao3.   

Abstract

Obesity-associated insulin resistance is a forerunner of type 2 diabetes. Macrophages reside within adipose tissue (ATMs) have been reported to regulate insulin sensitivity through secreting miRNAs containing exosomes. Here, we show that miR-29a is increased in obese ATMs derived exosomes (ATMs-Exos) and can be transferred into adipocytes, myocytes and hepatocytes causing insulin resistance in vitro and in vivo. Administration of obese ATMs-Exos impairs insulin sensitivity of lean mice. While knockdown miR-29a level in obese ATM-Exos blunts this effect. PPAR-δ is identified to function as downstream target of miR-29a in regulating insulin resistance. PPAR-δ agonist GW501516 partially rescued the insulin resistance induced by miR-29a. Taken together, these findings suggest that ATMs derived exosomal miR-29a could regulate obesity-associated insulin resistance, which may serve as a potential therapeutic target for obesity-associated type 2 diabetes.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ATMs; Exosomes; Insulin resistance; PPAR-δ; miRNAs

Mesh:

Substances:

Year:  2019        PMID: 31153636     DOI: 10.1016/j.bbrc.2019.05.113

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  35 in total

Review 1.  Exosomal Secretion of Adipose Tissue during Various Physiological States.

Authors:  Menchus Quan; Shihuan Kuang
Journal:  Pharm Res       Date:  2020-10-15       Impact factor: 4.200

Review 2.  Why does obesity cause diabetes?

Authors:  Samuel Klein; Amalia Gastaldelli; Hannele Yki-Järvinen; Philipp E Scherer
Journal:  Cell Metab       Date:  2022-01-04       Impact factor: 27.287

Review 3.  Exosomes as mediators of intercellular crosstalk in metabolism.

Authors:  Roi Isaac; Felipe Castellani Gomes Reis; Wei Ying; Jerrold M Olefsky
Journal:  Cell Metab       Date:  2021-09-07       Impact factor: 31.373

Review 4.  GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?

Authors:  Maurício Reis Pedrosa; Denise Reis Franco; Hannah Waisberg Gieremek; Camila Maia Vidal; Fernanda Bronzeri; Alexia de Cassia Rocha; Luis Gabriel de Carvalho Cara; Sofia Lenzi Fogo; Freddy Goldberg Eliaschewitz
Journal:  Curr Atheroscler Rep       Date:  2022-08-31       Impact factor: 5.967

Review 5.  Extracellular Vesicles in Pathogenesis and Treatment of Metabolic Associated Fatty Liver Disease.

Authors:  Ji Sun; Dianbao Zhang; Yiling Li
Journal:  Front Physiol       Date:  2022-06-13       Impact factor: 4.755

Review 6.  The Roles of Adipose Tissue Macrophages in Human Disease.

Authors:  Weizheng Liang; Yanxu Qi; Hongyang Yi; Chenyu Mao; Qingxue Meng; Hao Wang; Chunfu Zheng
Journal:  Front Immunol       Date:  2022-06-09       Impact factor: 8.786

Review 7.  Macrophage-Derived Small Extracellular Vesicles in Multiple Diseases: Biogenesis, Function, and Therapeutic Applications.

Authors:  Jingyao Ye; Xuehong Liu
Journal:  Front Cell Dev Biol       Date:  2022-06-27

8.  Associations Among Adipose Tissue Immunology, Inflammation, Exosomes and Insulin Sensitivity in People With Obesity and Nonalcoholic Fatty Liver Disease.

Authors:  Anja Fuchs; Dmitri Samovski; Gordon I Smith; Vincenza Cifarelli; Sarah S Farabi; Jun Yoshino; Terri Pietka; Shin-Wen Chang; Sarbani Ghosh; Terence M Myckatyn; Samuel Klein
Journal:  Gastroenterology       Date:  2021-05-15       Impact factor: 33.883

Review 9.  Epigenetics, microRNA and Metabolic Syndrome: A Comprehensive Review.

Authors:  Farha Ramzan; Mark H Vickers; Richard F Mithen
Journal:  Int J Mol Sci       Date:  2021-05-10       Impact factor: 5.923

Review 10.  Extracellular vesicle activities regulating macrophage- and tissue-mediated injury and repair responses.

Authors:  Qian Hu; Christopher J Lyon; Jesse K Fletcher; Wenfu Tang; Meihua Wan; Tony Y Hu
Journal:  Acta Pharm Sin B       Date:  2020-12-19       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.